Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for C4 Therapeutics, Inc. (CCCC : NSDQ)

• Company Description    C4 Therapeutics Inc. is a biopharmaceutical company. It is focused on harnessing the body's natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. C4 Therapeutics Inc. is based in WATERTOWN, Mass. Number of Employees: 121

• Price / Volume Information    Yesterday's Closing Price: $6.71 Daily Weekly Monthly 20 Day Moving Average: 806,499 shares Shares Outstanding: 48.80 (millions) Market Capitalization: $327.43 (millions) Beta: 2.77 52 Week High: $51.21 52 Week Low: $6.26 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -26.34% -19.29% 12 Week -67.97% -65.25% Year To Date -79.16% -75.22%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 490 Arsenal Way Suite 200 - Watertown,MA 02472 USA ph: 617-231-0700 fax: - kendra.adams@c4therapeutics.com https://c4therapeutics.com

• General Corporate Information    Officers Andrew J. Hirsch - President and Chief Executive Officer Marc A. Cohen - Executive Chairman Lauren A. White - Chief Financial Officer Alain J. Cohen - Director Bruce Downey - Director Peer Information C4 Therapeutics, Inc. (CORR.) C4 Therapeutics, Inc. (RSPI) C4 Therapeutics, Inc. (CGXP) C4 Therapeutics, Inc. (BGEN) C4 Therapeutics, Inc. (GTBP) C4 Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 12529R107 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/10/22 Share - Related Items Shares Outstanding: 48.80 Most Recent Split Date: (:1) Beta: 2.77 Market Capitalization: $327.43 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.68 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.85 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 20.77% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/10/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.90 Price/Cash Flow: - Price / Sales: 7.12 EPS Growth vs. Year Ago Period: -32.65% vs. Previous Quarter: -109.68% Sales Growth vs. Year Ago Period: 3.07% vs. Previous Quarter: -61.88% ROE 03/31/22 - -24.10 12/31/21 - -22.85 09/30/21 - -26.49 ROA 03/31/22 - -18.37 12/31/21 - -17.50 09/30/21 - -19.89 Current Ratio 03/31/22 - 6.45 12/31/21 - 6.36 09/30/21 - 8.47 Quick Ratio 03/31/22 - 6.45 12/31/21 - 6.36 09/30/21 - 8.47 Operating Margin 03/31/22 - -205.47 12/31/21 - -183.23 09/30/21 - -265.03 Net Margin 03/31/22 - -205.47 12/31/21 - -183.23 09/30/21 - -265.03 Pre-Tax Margin 03/31/22 - -205.47 12/31/21 - -183.23 09/30/21 - -265.40 Book Value 03/31/22 - 7.47 12/31/21 - 8.01 09/30/21 - 8.21 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.03 12/31/21 - 0.03 09/30/21 - 0.03 Debt-to-Capital 03/31/22 - 2.72 12/31/21 - 2.69 09/30/21 - 2.59

Powered by Zacks Investment Research ©